• Target：
• BRCA1

• Fields：
• >>Platinum drug resistance;>>Homologous recombination;>>Fanconi anemia pathway;>>Ubiquitin mediated proteolysis;>>PI3K-Akt signaling pathway;>>MicroRNAs in cancer;>>Breast cancer

• Gene Name：
• BRCA1 RNF53

• Protein Name：
• Breast cancer type 1 susceptibility protein (EC 6.3.2.-) (RING finger protein 53)

• Sequence：
• P38398

• Human Gene Id：
• 672

• Human Swiss Prot No：
• P38398

• Mouse Gene Id：
• 12189

• Mouse Swiss Prot No：
• P48754

• Rat Gene Id：
• 497672

• Rat Swiss Prot No：
• O54952

• Immunogen：
• Synthesized peptide derived from human BRCA1 (Phospho Ser1497)

• Specificity：
• This antibody detects endogenous levels of BRCA1 (Phospho Ser1497) Rabbit pAb at Human, Mouse,Rat

• Formulation：
• Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.

• Source：
• Rabbit,polyclonal

• Dilution：
• WB 1:500-2000 IHC 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• Breast cancer type 1 susceptibility protein (EC 6.3.2.-) (RING finger protein 53)

• Molecular Weight(Da)：
• 205kD

• Background：
• BRCA1, DNA repair associated(BRCA1) Homo sapiens This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript varian

• Function：
• disease:Defects in BRCA1 are a cause of genetic susceptibility to breast cancer (BC) [MIM:113705, 114480]. BC is an extremely common malignancy, affecting one in eight women during their lifetime. A positive family history has been identified as major contributor to risk of development of the disease, and this link is striking for early-onset breast cancer. Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.,disease:Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705].,disease:Defects in BRCA1 are a cause of susceptibility to familial breast-ovarian cancer type 1 (BROVCA1) [MIM:604370]. Mutations in BRCA1 are

• Subcellular Location：
• Nucleus . Chromosome . Cytoplasm . Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by ABRAXAS1 and the BRCA1-A complex (PubMed:26778126). Translocated to the cytoplasm during UV-induced apoptosis (PubMed:20160719). .; [Isoform 3]: Cytoplasm.; [Isoform 5]: Cytoplasm .

• Expression：
• Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs